Asparaginase encapsulated in erythrocytes as second‐line treatment in hypersensitive patients with acute lymphoblastic leukaemia-Reference-Cited by-同舟云学术

Asparaginase encapsulated in erythrocytes as second‐line treatment in hypersensitive patients with acute lymphoblastic leukaemia

Published:2022-03-28 Issue:6 Volume:197 Page:745-754
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Lynggaard Line Stensig¹²^ORCID,Vaitkeviciene Goda³,Langenskiöld Cecilia⁴,Lehmann Anne Kristine⁵,Lähteenmäki Päivi M.⁶,Lepik Kristi⁷,El Hariry Iman⁸,Schmiegelow Kjeld⁹¹⁰,Albertsen Birgitte Klug¹²^ORCID

Affiliation:

1. Department of Paediatrics and Adolescent Medicine Aarhus University Hospital Aarhus Denmark

2. Department of Clinical Medicine Aarhus University Aarhus Denmark

3. Center of Pediatric Oncology and Hematology Vilnius University Hospital Santaros Klinikos and Vilnius University Vilnius Lithuania

4. Institute of Clinical Sciences Gothenburg University Gothenburg Sweden

5. Department of Hematology Haukeland Universitetssjukehus Bergen Norway

6. Department of Pediatric and Adolescent Medicine Turku University Hospital Turku Finland

7. Department of Hematology and Oncology Tallinn Children's Hospital Tallinn Estonia

8. Erytech Cambridge Massachusetts USA

9. Department of Pediatrics and Adolescent Medicine, Rigshospitalet University of Copenhagen Copenhagen Denmark

10. Institute of Clinical Medicine, Faculty of Medicine University of Copenhagen Copenhagen Denmark

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.18152

Reference31 articles.

1. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study

2. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01

3. Therapeutic impact of extended high‐dose asparaginase during continuation therapy for standard‐risk childhood acute lymphoblastic leukemia. Long term results of the IDH‐ALL‐91 trial of the International BFM Study Group;Arico M;Blood,2003

4. Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy

5. Relapse risk following truncation of pegylated asparaginase in childhood acute lymphoblastic leukemia

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New insights into red blood cells in tumor precision diagnosis and treatment;Nanoscale;2024

2. Erythrocyte-based Drug Delivery: How Far from Clinical Application?;Current Drug Delivery;2024-01

3. Prediction of Oscillations in Glycolysis in Ethanol-Consuming Erythrocyte-Bioreactors;International Journal of Molecular Sciences;2023-06-14

4. Preclinical and clinical developments in enzyme-loaded red blood cells: an update;Expert Opinion on Drug Delivery;2023-06-06

5. L-asparaginase anti-tumor activity in pancreatic cancer is dependent on its glutaminase activity and resistance is mediated by glutamine synthetase;Experimental Cell Research;2023-05